A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Investigate the Safety and Exploratory Efficacy of a Subdermal Implant-bioabsorbable Gestrinone Pellet for Pelvic Pain Secondary to Endometriosis Treatment
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Levonorgestrel (Primary) ; Gestrinone
- Indications Endometriosis
- Focus Adverse reactions
- Acronyms GLADE
Most Recent Events
- 01 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2024 Planned End Date changed from 1 Nov 2024 to 30 Apr 2025.
- 30 Oct 2024 Planned primary completion date changed from 1 Nov 2024 to 30 Apr 2025.